- Home
- GEN vs WAT Comparison
GEN vs WAT Comparison
Compare GEN & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEN
- WAT
- Stock Information
- Founded
- GEN 1982
- WAT 1958
- Country
- GEN United States
- WAT United States
- Employees
- GEN N/A
- WAT N/A
- Industry
- GEN Computer Software: Prepackaged Software
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- GEN Technology
- WAT Industrials
- Exchange
- GEN Nasdaq
- WAT Nasdaq
- Market Cap
- GEN 18.6B
- WAT 17.4B
- IPO Year
- GEN N/A
- WAT 1995
- Fundamental
- Price
- GEN $27.35
- WAT $351.27
- Analyst Decision
- GEN Buy
- WAT Buy
- Analyst Count
- GEN 7
- WAT 15
- Target Price
- GEN $35.71
- WAT $373.13
- AVG Volume (30 Days)
- GEN 3.1M
- WAT 688.2K
- Earning Date
- GEN 11-06-2025
- WAT 11-04-2025
- Dividend Yield
- GEN 1.84%
- WAT N/A
- EPS Growth
- GEN 1.17
- WAT 10.77
- EPS
- GEN 0.96
- WAT 11.09
- Revenue
- GEN $4,227,000,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- GEN $24.68
- WAT $7.15
- Revenue Next Year
- GEN $5.06
- WAT $6.34
- P/E Ratio
- GEN $28.34
- WAT $31.58
- Revenue Growth
- GEN 10.60
- WAT 5.89
- 52 Week Low
- GEN $22.74
- WAT $275.05
- 52 Week High
- GEN $32.22
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- GEN 44.15
- WAT 72.86
- Support Level
- GEN $26.32
- WAT $323.46
- Resistance Level
- GEN $27.23
- WAT $338.37
- Average True Range (ATR)
- GEN 0.51
- WAT 9.65
- MACD
- GEN 0.04
- WAT 2.03
- Stochastic Oscillator
- GEN 54.05
- WAT 70.72
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.